abstract: OBJECTIVE: To compare changes of body water measured by using bioelectrical impedance analysis (BIA), between @entity4 and @entity3 therapy. MATERIAL AND METHOD: This is a prospective randomized open-label study in @entity2 outpatients. Eighty @entity0 were randomized into two groups; 1) @entity3 5 mg/d and 2) @entity4 10 mg/d. @entity0 were assessed for changes in total body water (TBW), extracellular water (ECW) and intracellular water (ICW) at week 4 and 8 after treatment. RESULTS: At baseline body water in both groups were similar. After treatment, both groups did not have significant changes in body water from baseline. Seven @entity0 in @entity3 group (17.5%) and none of @entity4 group developed @entity1 ; p = 0.012. Among those seven @entity0 , TBW, ECW and ICW all increased significantly from baseline. CONCLUSION: BIA did not detected changes of body water in most @entity0 . However, in @entity0 who developed @entity1 , TBW, ECW and LCW significantly increased from baseline with the greatest changes seen in extracellular compartment.

title: Comparison of changes of body water measured by using bioelectrical impedance analysis between XXXX and @entity3 therapy in @entity2 outpatients.

answer: @entity4


abstract: OBJECTIVE: To compare changes of body water measured by using bioelectrical impedance analysis (BIA), between @entity4 and @entity3 therapy. MATERIAL AND METHOD: This is a prospective randomized open-label study in @entity2 outpatients. Eighty @entity0 were randomized into two groups; 1) @entity3 5 mg/d and 2) @entity4 10 mg/d. @entity0 were assessed for changes in total body water (TBW), extracellular water (ECW) and intracellular water (ICW) at week 4 and 8 after treatment. RESULTS: At baseline body water in both groups were similar. After treatment, both groups did not have significant changes in body water from baseline. Seven @entity0 in @entity3 group (17.5%) and none of @entity4 group developed @entity1 ; p = 0.012. Among those seven @entity0 , TBW, ECW and ICW all increased significantly from baseline. CONCLUSION: BIA did not detected changes of body water in most @entity0 . However, in @entity0 who developed @entity1 , TBW, ECW and LCW significantly increased from baseline with the greatest changes seen in extracellular compartment.

title: Comparison of changes of body water measured by using bioelectrical impedance analysis between @entity4 and XXXX therapy in @entity2 outpatients.

answer: @entity3


abstract: OBJECTIVE: To compare changes of body water measured by using bioelectrical impedance analysis (BIA), between @entity4 and @entity3 therapy. MATERIAL AND METHOD: This is a prospective randomized open-label study in @entity2 outpatients. Eighty @entity0 were randomized into two groups; 1) @entity3 5 mg/d and 2) @entity4 10 mg/d. @entity0 were assessed for changes in total body water (TBW), extracellular water (ECW) and intracellular water (ICW) at week 4 and 8 after treatment. RESULTS: At baseline body water in both groups were similar. After treatment, both groups did not have significant changes in body water from baseline. Seven @entity0 in @entity3 group (17.5%) and none of @entity4 group developed @entity1 ; p = 0.012. Among those seven @entity0 , TBW, ECW and ICW all increased significantly from baseline. CONCLUSION: BIA did not detected changes of body water in most @entity0 . However, in @entity0 who developed @entity1 , TBW, ECW and LCW significantly increased from baseline with the greatest changes seen in extracellular compartment.

title: Comparison of changes of body water measured by using bioelectrical impedance analysis between @entity4 and @entity3 therapy in XXXX outpatients.

answer: @entity2


abstract: Magnetic seed treatment is one of the physical pre-sowing seed treatments to enhance the performance of crop plants. In our earlier experiment, we found significant increase in germination and vigour characteristics of @entity1 ( @entity1 .) seeds subjected to magnetic fields. Among various combinations of @entity0 ( @entity0 ) strength and duration, best results were obtained with @entity0 of 100 mT for 2 h and 200 mT for 1 h exposure. The quicker germination in magnetically-exposed seeds might be due to greater activities of germination related enzymes, early hydration of membranes as well as greater molecular mobility of bulk and hydration water fractions. Thus, in the present study, changes in water uptake during imbibition and its distribution and activities of germinating enzymes during germination were investigated in @entity1 seeds exposed to static magnetic fields of 100 and 200 mT for 2 and 1 h respectively by nuclear magnetic resonance (NMR) spectroscopy. The magnetically-exposed seed showed higher water uptake in phase II and III than unexposed seed. The longitudinal relaxation time T1 of seed water showed significantly higher values and hence greater molecular mobility of cellular water in magnetically-exposed seeds as compared to unexposed. Component analysis of T2 relaxation times revealed the early appearance of hydration water with least mobility and higher values of relaxation times of cytoplasmic bulk water and hydration water in magnetically-exposed over unexposed seeds. Activities of @entity2 , dehydorgenase and protease during germination were higher in magnetically-exposed seeds as compared to unexposed. The quicker germination in magnetically-exposed seeds might be due to greater activities of germination related enzymes, early hydration of membranes as well as greater molecular mobility of bulk and hydration water fractions.

title: Characterization of water distribution and activities of enzymes during germination in magnetically-exposed XXXX ( @entity1 ) seeds.

answer: @entity1


abstract: Magnetic seed treatment is one of the physical pre-sowing seed treatments to enhance the performance of crop plants. In our earlier experiment, we found significant increase in germination and vigour characteristics of @entity1 ( @entity1 .) seeds subjected to magnetic fields. Among various combinations of @entity0 ( @entity0 ) strength and duration, best results were obtained with @entity0 of 100 mT for 2 h and 200 mT for 1 h exposure. The quicker germination in magnetically-exposed seeds might be due to greater activities of germination related enzymes, early hydration of membranes as well as greater molecular mobility of bulk and hydration water fractions. Thus, in the present study, changes in water uptake during imbibition and its distribution and activities of germinating enzymes during germination were investigated in @entity1 seeds exposed to static magnetic fields of 100 and 200 mT for 2 and 1 h respectively by nuclear magnetic resonance (NMR) spectroscopy. The magnetically-exposed seed showed higher water uptake in phase II and III than unexposed seed. The longitudinal relaxation time T1 of seed water showed significantly higher values and hence greater molecular mobility of cellular water in magnetically-exposed seeds as compared to unexposed. Component analysis of T2 relaxation times revealed the early appearance of hydration water with least mobility and higher values of relaxation times of cytoplasmic bulk water and hydration water in magnetically-exposed over unexposed seeds. Activities of @entity2 , dehydorgenase and protease during germination were higher in magnetically-exposed seeds as compared to unexposed. The quicker germination in magnetically-exposed seeds might be due to greater activities of germination related enzymes, early hydration of membranes as well as greater molecular mobility of bulk and hydration water fractions.

title: Characterization of water distribution and activities of enzymes during germination in magnetically-exposed @entity1 ( XXXX ) seeds.

answer: @entity1


abstract: BACKGROUND: @entity3 75mcg is being used for the prevention of @entity2 . However, weight-adjusted doses in laparoscopic surgery are unevaluated. AIM: To determine the response to three doses of @entity3 (0.5, 1.0, or 1.5mcgkg) over 72h in the postoperative period in @entity0 undergoing laparoscopic gynaecological procedures. DESIGN: A randomised dose-response study. SETTING: A tertiary care hospital and research institute in north India from July to December 2014. @entity0 : American society of Anesthesiologists physical status I and II @entity0 , from 18 to 60 years old, undergoing laparoscopic gynaecological procedures on a day care basis. METHODS: @entity0 were randomised to receive @entity3 0.5, 1 and 1.5mcgkg intravenously before induction of anaesthesia. MAIN OUTCOMES MEASURES: The primary outcome was the proportion of @entity0 with a complete response (i.e. who neither vomited nor required additional antiemetic drugs for @entity1 during the first 72 postoperative hours). The proportion of @entity0 having @entity1 or emetic episodes and the requirement for rescue antiemetics and analgesics during the 72-h period were recorded as secondary outcomes. RESULTS: With @entity3 , there was a significant dose-dependent increase (37.5 vs. 67.5 vs. 75%, P<0.001) in proportion of @entity0 with a complete response during the 72h. This was associated with a significant dose-dependent decrease in the proportion of @entity0 with @entity1 (77.5 vs. 47.5 vs. 35%, P<0.001) and vomiting (47.5 vs. 32.5 vs. 12.5%, P=0.003). CONCLUSION: Following laparoscopic gynaecological surgery, intravenous @entity3 has a dose-dependent prophylactic effect against @entity2 during the first 72 postoperative hours. TRIAL REGISTRATION: The trial was registered with Clinical trial registry of India(CTRI/2014/09/004987).

title: Evaluation of weight-adjusted doses of @entity3 for prevention of XXXX in day care laparoscopic gynaecological surgery: A dose ranging, randomised controlled trial.

answer: @entity2


abstract: BACKGROUND: @entity3 75mcg is being used for the prevention of @entity2 . However, weight-adjusted doses in laparoscopic surgery are unevaluated. AIM: To determine the response to three doses of @entity3 (0.5, 1.0, or 1.5mcgkg) over 72h in the postoperative period in @entity0 undergoing laparoscopic gynaecological procedures. DESIGN: A randomised dose-response study. SETTING: A tertiary care hospital and research institute in north India from July to December 2014. @entity0 : American society of Anesthesiologists physical status I and II @entity0 , from 18 to 60 years old, undergoing laparoscopic gynaecological procedures on a day care basis. METHODS: @entity0 were randomised to receive @entity3 0.5, 1 and 1.5mcgkg intravenously before induction of anaesthesia. MAIN OUTCOMES MEASURES: The primary outcome was the proportion of @entity0 with a complete response (i.e. who neither vomited nor required additional antiemetic drugs for @entity1 during the first 72 postoperative hours). The proportion of @entity0 having @entity1 or emetic episodes and the requirement for rescue antiemetics and analgesics during the 72-h period were recorded as secondary outcomes. RESULTS: With @entity3 , there was a significant dose-dependent increase (37.5 vs. 67.5 vs. 75%, P<0.001) in proportion of @entity0 with a complete response during the 72h. This was associated with a significant dose-dependent decrease in the proportion of @entity0 with @entity1 (77.5 vs. 47.5 vs. 35%, P<0.001) and vomiting (47.5 vs. 32.5 vs. 12.5%, P=0.003). CONCLUSION: Following laparoscopic gynaecological surgery, intravenous @entity3 has a dose-dependent prophylactic effect against @entity2 during the first 72 postoperative hours. TRIAL REGISTRATION: The trial was registered with Clinical trial registry of India(CTRI/2014/09/004987).

title: Evaluation of weight-adjusted doses of XXXX for prevention of @entity2 in day care laparoscopic gynaecological surgery: A dose ranging, randomised controlled trial.

answer: @entity3


abstract: UNASSIGNED: Background: No current studies regarding saw injuries have been published in German literature for quite some time. Despite awareness measures and safety instructions, saw accidents along with @entity2 are the most common causes of @entity3 . Approximately 12,000 circular saw injuries occur in Germany each year. Since professional providers have increased prices due to the rising energy costs and a wide range of different home appliance saws are available, increasing use has been made of portable circular saws in the do-it-yourself market sector. @entity0 and methods: At our hospital, we evaluated the data of 51 male @entity0 with saw injuries. The present study investigated factors that may contribute to accidents involving saws. Results: 80% of the accidents occurred at home, usually on weekends or after work. 51% of the accidents happened while @entity0 cut firewood. In 84% of the cases, an electric table saw was used. The majority of @entity3 were sustained with lower priced saws. @entity2 occurred most frequently between 11   a.m. and 2   p.m., primarily with @entity1 . Replantable amputations or partial amputations occured rarely. In 37% of the @entity0 , anatomical reconstruction using osteosynthesis and/or microsurgical techniques was performed successfully. Conclusions: Saw injuries to the hand are sustained almost exclusively by @entity0 . Serious injuries from low-priced table saws and due to the lack of protective covering are predominant. Preventive measures and mandatory training could reduce the number of saw injuries in the years to come. The results obtained by us largely confirm the data from previous publications.

title: [Saw XXXX to the Hand - Epidemiological Aspects].

answer: @entity2


abstract: UNASSIGNED: Objective @entity5 is a common cause of chronic @entity4 in the Scandinavian countries. This report comprises demographic data, clinical and endoscopic features, and occurrence of @entity1 ( @entity1 ) in a large urban cohort of @entity0 with @entity8 ( @entity8 ) and @entity6 ( @entity6 ). Materials and methods A total of 795 @entity0 with @entity5 from two hospitals in Stockholm were included. Medical records were reviewed and clinical data, including endoscopic and histological findings, were compiled. Results Forty-three percent had @entity6 (female:male ratio 3.7:1) and 57% had @entity8 (female:male ratio 2.7:1). The mean age at diagnosis of @entity6 was 63 years and of @entity8 was 59 years (p   =   0.005). Clinical features were similar in both entities, but the intensity of symptoms differed. Watery @entity4 was reported in 55% in @entity6 @entity0 versus in 43% in @entity8 @entity0 (p   =   0.0014), and nocturnal @entity4 in 28% versus 18% (p   =   0.002). Subtle endoscopic mucosal findings were reported in 37% of the @entity6 @entity0 and in 25% of the @entity8 @entity0 (p   =   0.0011). @entity7 were found in 5.3% of all @entity0 . @entity3 occurred in 6% and @entity1 occurred in 2.1% of all @entity0 . Conclusions Clinical features of @entity8 and @entity6 are similar but not identical. @entity6 seems to be a more @entity2 and @entity8 tends to occur earlier in life. Both forms might indeed feature endoscopic findings despite the designation 'microscopic'. Our study confirms the strong association with @entity3 .

title: XXXX : a descriptive clinical cohort study of 795 @entity0 with collagenous and @entity8 .

answer: @entity5


abstract: UNASSIGNED: Objective @entity5 is a common cause of chronic @entity4 in the Scandinavian countries. This report comprises demographic data, clinical and endoscopic features, and occurrence of @entity1 ( @entity1 ) in a large urban cohort of @entity0 with @entity8 ( @entity8 ) and @entity6 ( @entity6 ). Materials and methods A total of 795 @entity0 with @entity5 from two hospitals in Stockholm were included. Medical records were reviewed and clinical data, including endoscopic and histological findings, were compiled. Results Forty-three percent had @entity6 (female:male ratio 3.7:1) and 57% had @entity8 (female:male ratio 2.7:1). The mean age at diagnosis of @entity6 was 63 years and of @entity8 was 59 years (p   =   0.005). Clinical features were similar in both entities, but the intensity of symptoms differed. Watery @entity4 was reported in 55% in @entity6 @entity0 versus in 43% in @entity8 @entity0 (p   =   0.0014), and nocturnal @entity4 in 28% versus 18% (p   =   0.002). Subtle endoscopic mucosal findings were reported in 37% of the @entity6 @entity0 and in 25% of the @entity8 @entity0 (p   =   0.0011). @entity7 were found in 5.3% of all @entity0 . @entity3 occurred in 6% and @entity1 occurred in 2.1% of all @entity0 . Conclusions Clinical features of @entity8 and @entity6 are similar but not identical. @entity6 seems to be a more @entity2 and @entity8 tends to occur earlier in life. Both forms might indeed feature endoscopic findings despite the designation 'microscopic'. Our study confirms the strong association with @entity3 .

title: @entity5 : a descriptive clinical cohort study of 795 @entity0 with collagenous and XXXX .

answer: @entity8


abstract: UNASSIGNED: Objective @entity5 is a common cause of chronic @entity4 in the Scandinavian countries. This report comprises demographic data, clinical and endoscopic features, and occurrence of @entity1 ( @entity1 ) in a large urban cohort of @entity0 with @entity8 ( @entity8 ) and @entity6 ( @entity6 ). Materials and methods A total of 795 @entity0 with @entity5 from two hospitals in Stockholm were included. Medical records were reviewed and clinical data, including endoscopic and histological findings, were compiled. Results Forty-three percent had @entity6 (female:male ratio 3.7:1) and 57% had @entity8 (female:male ratio 2.7:1). The mean age at diagnosis of @entity6 was 63 years and of @entity8 was 59 years (p   =   0.005). Clinical features were similar in both entities, but the intensity of symptoms differed. Watery @entity4 was reported in 55% in @entity6 @entity0 versus in 43% in @entity8 @entity0 (p   =   0.0014), and nocturnal @entity4 in 28% versus 18% (p   =   0.002). Subtle endoscopic mucosal findings were reported in 37% of the @entity6 @entity0 and in 25% of the @entity8 @entity0 (p   =   0.0011). @entity7 were found in 5.3% of all @entity0 . @entity3 occurred in 6% and @entity1 occurred in 2.1% of all @entity0 . Conclusions Clinical features of @entity8 and @entity6 are similar but not identical. @entity6 seems to be a more @entity2 and @entity8 tends to occur earlier in life. Both forms might indeed feature endoscopic findings despite the designation 'microscopic'. Our study confirms the strong association with @entity3 .

title: @entity5 : a descriptive clinical cohort study of 795 XXXX with collagenous and @entity8 .

answer: @entity0


abstract: PURPOSE: @entity1 and @entity7 ( @entity7 ) are two compounds with reproducible activity against advanced @entity8 . To evaluate the activity and feasibility of this combination chemotherapy, a multi-institutional phase II study was performed. MATERIALS AND METHODS: Twenty @entity0 (male: female 15: 5, median age: 60.5 years), with histologically verified locally advanced or metastatic @entity8 , were enrolled between April 2000 and March 2002. @entity1 was administered by intravenous injection at the doses of 1, 000 mg/m2 on days 1, 8 and 15, and @entity7 800 mg/m2/day, was given by continuous intravenous infusion on days 1~5. The treatment was repeated every 4 weeks. The clinical benefit response (CBR) was a composite of the @entity3 , Karnofsky performance status and body weight change measurement. RESULTS: Nineteen of the twenty @entity0 were assessable for response. The median follow-up duration was 4.6 months (0.4~15.2 months). Five @entity0 achieved a partial response and eight a stable disease. The overall response rate was 25.0%. The CBR was assessable in 12 @entity0 . The overall CBR was 41.7% (5/12). The median survival of all the @entity0 was 8.0 months. Grade 3~4 @entity2 included @entity6 (9.3%) and @entity5 (5.3%). CONCLUSION: This study suggested that @entity1 , combined with infusional @entity7 , was well tolerated, and produced modest antitumor activity and symptomatic relief in advanced @entity4 @entity0 .

title: @entity1 and Infusional @entity7 in Advanced XXXX : A Clinical Benefit Response-Oriented Phase II Study.

answer: @entity4


abstract: PURPOSE: @entity1 and @entity7 ( @entity7 ) are two compounds with reproducible activity against advanced @entity8 . To evaluate the activity and feasibility of this combination chemotherapy, a multi-institutional phase II study was performed. MATERIALS AND METHODS: Twenty @entity0 (male: female 15: 5, median age: 60.5 years), with histologically verified locally advanced or metastatic @entity8 , were enrolled between April 2000 and March 2002. @entity1 was administered by intravenous injection at the doses of 1, 000 mg/m2 on days 1, 8 and 15, and @entity7 800 mg/m2/day, was given by continuous intravenous infusion on days 1~5. The treatment was repeated every 4 weeks. The clinical benefit response (CBR) was a composite of the @entity3 , Karnofsky performance status and body weight change measurement. RESULTS: Nineteen of the twenty @entity0 were assessable for response. The median follow-up duration was 4.6 months (0.4~15.2 months). Five @entity0 achieved a partial response and eight a stable disease. The overall response rate was 25.0%. The CBR was assessable in 12 @entity0 . The overall CBR was 41.7% (5/12). The median survival of all the @entity0 was 8.0 months. Grade 3~4 @entity2 included @entity6 (9.3%) and @entity5 (5.3%). CONCLUSION: This study suggested that @entity1 , combined with infusional @entity7 , was well tolerated, and produced modest antitumor activity and symptomatic relief in advanced @entity4 @entity0 .

title: @entity1 and Infusional XXXX in Advanced @entity4 : A Clinical Benefit Response-Oriented Phase II Study.

answer: @entity7


abstract: PURPOSE: @entity1 and @entity7 ( @entity7 ) are two compounds with reproducible activity against advanced @entity8 . To evaluate the activity and feasibility of this combination chemotherapy, a multi-institutional phase II study was performed. MATERIALS AND METHODS: Twenty @entity0 (male: female 15: 5, median age: 60.5 years), with histologically verified locally advanced or metastatic @entity8 , were enrolled between April 2000 and March 2002. @entity1 was administered by intravenous injection at the doses of 1, 000 mg/m2 on days 1, 8 and 15, and @entity7 800 mg/m2/day, was given by continuous intravenous infusion on days 1~5. The treatment was repeated every 4 weeks. The clinical benefit response (CBR) was a composite of the @entity3 , Karnofsky performance status and body weight change measurement. RESULTS: Nineteen of the twenty @entity0 were assessable for response. The median follow-up duration was 4.6 months (0.4~15.2 months). Five @entity0 achieved a partial response and eight a stable disease. The overall response rate was 25.0%. The CBR was assessable in 12 @entity0 . The overall CBR was 41.7% (5/12). The median survival of all the @entity0 was 8.0 months. Grade 3~4 @entity2 included @entity6 (9.3%) and @entity5 (5.3%). CONCLUSION: This study suggested that @entity1 , combined with infusional @entity7 , was well tolerated, and produced modest antitumor activity and symptomatic relief in advanced @entity4 @entity0 .

title: XXXX and Infusional @entity7 in Advanced @entity4 : A Clinical Benefit Response-Oriented Phase II Study.

answer: @entity1


abstract: PURPOSE: The increased expression of @entity5 has been implicated in the development and progression of @entity0 @entity1 . This study investigated the @entity5 expression in @entity2 , and its relationships with @entity1 angiogenesis and the clinicopathological factors. MATERIALS AND METHODS: The expression of the @entity5 protein and microvessel density were evaluated, using immunohistochemical methods, in 21 normal colonic mucosa and 190 @entity0 @entity2 . Correlations between @entity5 expression and microvessel density, as well as various clinicopathological factors, were studied in @entity2 . RESULTS: The @entity5 protein expression in epithelial cells was increased in 169 of the 190 @entity3 cases (88.9%), but in only 1 of the 21 (4.8%) normal mucosa cases. The @entity5 expression was significantly increased in the differentiated compared with the undifferentiated @entity2 (p<0.05), and significantly correlated with the depth of invasion and microvessel density (p<0.05). @entity1 had more @entity5 positive cases than the @entity4 (p<0.05). However, there were no significant differences in the @entity1 size and the presence of @entity7 . CONCLUSION: The overexpression of @entity6 in @entity2 seems to play a role in the invasion and angiogenesis of the @entity1 , so may be a useful marker of the prognosis. The prominent expression was also demonstrated in differentiated @entity2 .

title: Expression of @entity6 and Tumor Microvessel Density in XXXX .

answer: @entity2


abstract: PURPOSE: The increased expression of @entity5 has been implicated in the development and progression of @entity0 @entity1 . This study investigated the @entity5 expression in @entity2 , and its relationships with @entity1 angiogenesis and the clinicopathological factors. MATERIALS AND METHODS: The expression of the @entity5 protein and microvessel density were evaluated, using immunohistochemical methods, in 21 normal colonic mucosa and 190 @entity0 @entity2 . Correlations between @entity5 expression and microvessel density, as well as various clinicopathological factors, were studied in @entity2 . RESULTS: The @entity5 protein expression in epithelial cells was increased in 169 of the 190 @entity3 cases (88.9%), but in only 1 of the 21 (4.8%) normal mucosa cases. The @entity5 expression was significantly increased in the differentiated compared with the undifferentiated @entity2 (p<0.05), and significantly correlated with the depth of invasion and microvessel density (p<0.05). @entity1 had more @entity5 positive cases than the @entity4 (p<0.05). However, there were no significant differences in the @entity1 size and the presence of @entity7 . CONCLUSION: The overexpression of @entity6 in @entity2 seems to play a role in the invasion and angiogenesis of the @entity1 , so may be a useful marker of the prognosis. The prominent expression was also demonstrated in differentiated @entity2 .

title: Expression of XXXX and Tumor Microvessel Density in @entity2 .

answer: @entity6


abstract: BACKGROUND: Food protein-induced @entity5 (FPIES) is an uncommon, non-IgE mediated food @entity3 that usually debuts in @entity2 , lethargy and pallor 2-4 hours following ingestion of the offending food. Its immune mechanism is not known. We aimed to describe the clinical features and outcome of @entity0 with fish-FPIES as well as to investigate on cellular immune response implicated. METHODS: Prospective and follow-up clinical study of @entity0 with FPIES by fish over a period between 2004-2013. Measurement in vitro of both cytokine production in peripheral blood mononuclear cells (PBMCs) and expression of HLA-DR in monocyte-derived dendritic cells, stimulated with fish extracts. RESULTS: Sixteen @entity0 (seven male and nine female) were included, with a mean age of onset at 10 months. Diagnosis was established after a median of 4 reactions. Twelve @entity0 were treated in emergency room, and two were admitted in intensive care. Patch tests were positive in six @entity0 . Skin prick tests (SPTs) and specific IgE to all fish tested were negative. Only three @entity0 reached tolerance at a mean age of 4.5 years. Eight @entity0 avoided fish because of positive @entity4 ( @entity4 ) after 6 years of age. Other @entity0 have not been challenged because of parent refusal to @entity4 or a recent diagnosis. @entity1 was increased in @entity0 and a significant elevation of the HLA-DR marker was also observed in these @entity0 vs control donors. CONCLUSIONS: FPIES caused by fish in many cases presents with severe clinical manifestations. Patch test has poor diagnostic value and @entity4 is the gold standard to test tolerance. The cytokine @entity1 may be implicated in the clinical symptoms. Higher expression of HLA-DR in dendritic cells has also been detected in our @entity0 . This article is protected by copyright. All rights reserved.

title: Clinical and immunological characteristics of a pediatric population with food protein-induced XXXX (FPIES) to fish.

answer: @entity5


abstract: We determined whether (1) long term antigen retention is present in distal sites after footpad challenge of immune @entity1 ; (2) if antigen retained in the foot is selectively localized; and (3) if the foot is adversely affected by the retained antigen. @entity1 immune or non-immune to human serum albumin (HSA) were injected in the hind footpads with 125I-HSA. In immune @entity1 rapid clearance of radiolabel occurred in the liver, lungs, kidney, blood and urine but radiolabel was retained in the hind feet, draining lymph nodes and spleen. Non-immune @entity1 rapidly cleared radiolabel from these sites. Autoradiography revealed that most of the radiolabel in the feet was @entity5 . Electron microscope autoradiography indicated that antigen was associated with collagen at the tendon surface, but not with cells or cell processes. Radiolabel solubilized from the feet, lymph nodes and spleen could be specifically precipitated with rabbit anti-HSA. Histological examination of the tendon and surrounding tissues did not show that retained antigen was causing @entity2 or chronic tissue damage. Nanogram levels of antigen could elicit swelling in the sensitized foot even if the antigen was injected at a remote site, but @entity1 immunized by other routes or against other antigens did not show @entity0 . Antigen retained on collagenous tissues may induce @entity3 and thus play a role in @entity4 .

title: Immune elimination and immune retention: the relationship between antigen retained in the foot and the elicitation of XXXX .

answer: @entity0


abstract: BACKGROUND: @entity4 ( @entity4 ) significantly contributes to the global burden of @entity1 . @entity2 is the third most frequent cause of @entity1 , with @entity4 representing more than 90% of primary @entity2 . During the last decade, much progress has been made with respect to the definition of @entity0 populations at risk who may benefit from surveillance strategies, as well as in the diagnosis and treatment of the disease. SUMMARY: New locoregional and systemic therapies have significantly increased the survival of @entity0 with @entity4 . A multitude of clinical trials addressing @entity0 with @entity4 have led to advancements in the allocation of subgroups of @entity0 to their optimal individual treatment strategy. This review provides an overview on recent developments in diagnostic and therapeutic modalities and an outlook on future directions in the management of @entity4 . KEY MESSAGE: New locoregional and systemic therapies in @entity0 with @entity4 have significantly improved clinical outlook and @entity0 survival. This review provides an overview of recent developments in diagnostics and therapeutics, as well as an outlook on future directions in the management of @entity4 . PRACTICAL IMPLICATIONS: Transabdominal ultrasound is the method of choice for the surveillance of @entity0 at risk of developing @entity4 , and any suspicious focal lesion in the liver should be characterized. Contrast-enhanced ultrasound with application of second-generation contrast agents enables visualization of @entity1 vascularity. The Barcelona Clinic @entity2 (BCLC) system is the most widely used classification system to guide the clinical management of @entity4 . Liver resection should be considered for @entity0 with well-preserved liver function and without portal @entity3 or elevated @entity5 . @entity0 not suitable for resection should undergo local @entity1 ablation. Candidates who are eligible for liver transplantation may benefit from bridging therapy during their waiting period. @entity0 in the BCLC B category benefit from locoregional transarterial therapy; transarterial chemoembolization is the treatment of choice. @entity7 is the only systemic therapy that has been shown to prolong overall survival in @entity0 with @entity6 , and is therefore recommended in @entity0 with well-preserved liver function.

title: XXXX : Current Concepts in Diagnosis, Staging and Treatment.

answer: @entity4


abstract: UNASSIGNED: @entity2 is rare. We aimed to evaluate survival outcome and prognostic factors for survival in @entity0 with @entity2 in recent years, marked by advancement in chemotherapy for @entity4 . All @entity0 treated for @entity2 at our institution between January 2000 and July 2013 were reviewed. Thirty-nine @entity0 were identified: 27 operative @entity0 [21(53.8%) curative and 6 (15.4%) palliative operations] and 12 nonoperative @entity0 [primary systemic chemotherapy, 4 (10.3%), palliative radiotherapy, 1 (2.6%), and no treatment, 7 (17.9%)]. Curative resections included 13 pancreaticoduodenectomies and eight segmental resections. Median @entity3 ( @entity3 ) for entire cohort was 14.4 months. Median @entity3 and one-, three-, and five-year @entity3 were operative group (41.4 months; 79.1%, 50.6%, and 10.6%, respectively); nonoperative group (7.4 months; 25.0%, 8.3%, and 0%, respectively); curative surgery (45.4 months; 92.9%, 62.5%, and 16.7%, respectively) and palliative surgery (5.4 months; 33.3%, 16.7%, and 0%, respectively). Female gender (P = 0.04), curative resection (P = 0.03), nodal @entity1 (P = 0.047) and advanced T stage (P = 0.047) were predictive of @entity3 . Two factors were independently predictive of @entity3 -female gender and curative resection. Overall survival still hinges on curative resection. This favors early detection. Adjuvant treatment modalities such as chemotherapy and radiation require further investigation.

title: XXXX : Profile and Predictors of Survival Outcomes.

answer: @entity2


abstract: BACKGROUND: It has been recently reported that the Romhilt-Estes (R-E) score, originally proposed for detection of left @entity3 from the electrocardiogram, is a strong predictor of all-cause mortality. Whether the R-E score is also predictive of @entity2 ( @entity2 ) and whether its individual components differ in their ability to predict different @entity2 outcomes are not well established. METHODS: This analysis includes 13,261 @entity0 from the ARIC study who were free of @entity2 at baseline (1987-1989). Incident @entity2 , @entity4 ( @entity4 ), @entity5 ( @entity5 ), and @entity1 were ascertained by an adjudication committee through December 2010. The R-E left @entity3 score was measured from automatically processed baseline electrocardiogram data. Cox proportional hazard models were used to examine the association between baseline the R-E overall score (overall) and each of its 6 individual components separately, with each of the @entity2 outcomes. RESULTS: During a median follow-up of 21.8 years, 3,579, 2,205, 1,814, and 731 @entity2 , @entity4 , @entity5 , and @entity1 events, respectively, occurred. In multivariable adjusted models, R-E score >= 4 points (compared with 0 points) was associated with increased risk of @entity2 , @entity4 , @entity5 , and @entity1 (hazard ratio [95% CI] 1.66 [1.41-1.96], 1.66 [1.34-2.07], 1.97 [1.60-2.43], and 1.49 [1.07-2.07], respectively). The 6 component of the R-E score varied in their relationship to different @entity2 outcomes. CONCLUSIONS: The R-E score is predictive of @entity2 outcomes. The 6 R-E score components differ in their associations with different @entity2 outcomes, indicating that they may be electrical biomarkers of different physiological events within the myocardium.

title: Individual components of the Romhilt-Estes left XXXX score differ in their prediction of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) study.

answer: @entity3


abstract: We examined transient and steady-state responses of the pulmonary circulation to @entity1 in isolated @entity3 lungs perfused with autologous blood. Responses were quantified by the pulmonary artery pressure at a flow of 1 l/min ( @entity4 ) read directly from pressure-flow recordings. Alveolar @entity2 tension was constant at 38 Torr and alveolar @entity0 pressure (PAO2) was varied between 670 and 0 Torr. When PAO2 was lowered progressively every 10 min, the relation between PAO2 and @entity4 was sigmoidal, with maximum constriction occurring at a PAO2 of 0 Torr; however, if @entity4 was allowed to reach a steady state at each level of PAO2, the relation was reproducibly and reversibly biphasic. @entity4 increased as PAO2 decreased from 670 to 60 Torr, was maximum and stable at PAO2 between 60 and 30 Torr, and decreased as PAO2 was lowered from 30 to 0 Torr. As a result, steady-state @entity4 at PAO2 greater than or equal to 200 Torr was similar to that at PAO2 = 0 Torr. When PAO2 was changed from 200 Torr to a constant lower level, @entity4 required 20-30 min to achieve a steady state at PAO2 greater than or equal to 25 Torr and 40-50 min at PAO2 of 10 and 0 Torr. With the latter, the responses consisted of vasoconstriction followed by marked vasodilation. Thus pulmonary vasomotor tone was a complex function of both PAO2 and time. Attempts to explain the pulmonary vascular response to @entity1 must take these complexities into account.

title: Vasodilator and constrictor responses to XXXX in isolated @entity3 lungs.

answer: @entity1


abstract: We examined transient and steady-state responses of the pulmonary circulation to @entity1 in isolated @entity3 lungs perfused with autologous blood. Responses were quantified by the pulmonary artery pressure at a flow of 1 l/min ( @entity4 ) read directly from pressure-flow recordings. Alveolar @entity2 tension was constant at 38 Torr and alveolar @entity0 pressure (PAO2) was varied between 670 and 0 Torr. When PAO2 was lowered progressively every 10 min, the relation between PAO2 and @entity4 was sigmoidal, with maximum constriction occurring at a PAO2 of 0 Torr; however, if @entity4 was allowed to reach a steady state at each level of PAO2, the relation was reproducibly and reversibly biphasic. @entity4 increased as PAO2 decreased from 670 to 60 Torr, was maximum and stable at PAO2 between 60 and 30 Torr, and decreased as PAO2 was lowered from 30 to 0 Torr. As a result, steady-state @entity4 at PAO2 greater than or equal to 200 Torr was similar to that at PAO2 = 0 Torr. When PAO2 was changed from 200 Torr to a constant lower level, @entity4 required 20-30 min to achieve a steady state at PAO2 greater than or equal to 25 Torr and 40-50 min at PAO2 of 10 and 0 Torr. With the latter, the responses consisted of vasoconstriction followed by marked vasodilation. Thus pulmonary vasomotor tone was a complex function of both PAO2 and time. Attempts to explain the pulmonary vascular response to @entity1 must take these complexities into account.

title: Vasodilator and constrictor responses to @entity1 in isolated XXXX lungs.

answer: @entity3


abstract: UNASSIGNED: Current evidences indicated that a group of soluble mediators called chemokines is involved in @entity2 growth and @entity1 . The association of @entity5 with @entity2 cell migration was previously found, and its expression was related to angiogenesis, @entity2 progression, and @entity1 in many kinds of @entity4 in @entity0 and animal models. Furthermore, it has been showed that @entity6 plays its role as either a proteome of @entity2 progression or antitumor indifferent @entity2 models. To investigate the messenger RNA (mRNA) expressions of @entity5 and @entity6 in @entity0 with @entity3 ( @entity3 ) and non- @entity2 tissue, quantitative real-time PCR was used in the study. Our results showed that expression of @entity5 mRNA was significantly increased in @entity2 tissues (mean        SD 3.84        0.08) compared with adjacent normal mucosa (mean        SD 1.17        0.75, P   =   0.001). Furthermore, a higher expression of @entity6 mRNA was found in @entity2 tissues (mean        SD 2.73        0.69) when compared with normal tissues (mean        SD 1.06        0.07, P   =   0.001). Our findings indicated that advanced @entity2 ( @entity2 ) stage (P   =   0.024) and histological grade (poorly differentiated, P   =   0.013) and distant @entity1 (P   =   0.001) were correlated with expression of @entity5 . Moreover, high expression of @entity6 showed significant association with early stage @entity3 ( @entity2 ) (P   =   0.038). In conclusion, the expression of @entity5 and @entity6 mRNAs was significantly increased in @entity2 tissues compared with adjacent normal tissues. We found that advanced @entity2 stage and histological grade and distant @entity1 were correlated with expression of @entity5 , while high expression of @entity6 showed significant association with early stage @entity3 ( @entity2 ) stage and overexpression of @entity5 may be associated with progression of @entity3 .

title: Overexpression of interleukins @entity6 and @entity5 with poor prognosis in XXXX induces @entity1 .

answer: @entity3


abstract: UNASSIGNED: Current evidences indicated that a group of soluble mediators called chemokines is involved in @entity2 growth and @entity1 . The association of @entity5 with @entity2 cell migration was previously found, and its expression was related to angiogenesis, @entity2 progression, and @entity1 in many kinds of @entity4 in @entity0 and animal models. Furthermore, it has been showed that @entity6 plays its role as either a proteome of @entity2 progression or antitumor indifferent @entity2 models. To investigate the messenger RNA (mRNA) expressions of @entity5 and @entity6 in @entity0 with @entity3 ( @entity3 ) and non- @entity2 tissue, quantitative real-time PCR was used in the study. Our results showed that expression of @entity5 mRNA was significantly increased in @entity2 tissues (mean        SD 3.84        0.08) compared with adjacent normal mucosa (mean        SD 1.17        0.75, P   =   0.001). Furthermore, a higher expression of @entity6 mRNA was found in @entity2 tissues (mean        SD 2.73        0.69) when compared with normal tissues (mean        SD 1.06        0.07, P   =   0.001). Our findings indicated that advanced @entity2 ( @entity2 ) stage (P   =   0.024) and histological grade (poorly differentiated, P   =   0.013) and distant @entity1 (P   =   0.001) were correlated with expression of @entity5 . Moreover, high expression of @entity6 showed significant association with early stage @entity3 ( @entity2 ) (P   =   0.038). In conclusion, the expression of @entity5 and @entity6 mRNAs was significantly increased in @entity2 tissues compared with adjacent normal tissues. We found that advanced @entity2 stage and histological grade and distant @entity1 were correlated with expression of @entity5 , while high expression of @entity6 showed significant association with early stage @entity3 ( @entity2 ) stage and overexpression of @entity5 may be associated with progression of @entity3 .

title: Overexpression of interleukins @entity6 and @entity5 with poor prognosis in @entity3 induces XXXX .

answer: @entity1


abstract: UNASSIGNED: Current evidences indicated that a group of soluble mediators called chemokines is involved in @entity2 growth and @entity1 . The association of @entity5 with @entity2 cell migration was previously found, and its expression was related to angiogenesis, @entity2 progression, and @entity1 in many kinds of @entity4 in @entity0 and animal models. Furthermore, it has been showed that @entity6 plays its role as either a proteome of @entity2 progression or antitumor indifferent @entity2 models. To investigate the messenger RNA (mRNA) expressions of @entity5 and @entity6 in @entity0 with @entity3 ( @entity3 ) and non- @entity2 tissue, quantitative real-time PCR was used in the study. Our results showed that expression of @entity5 mRNA was significantly increased in @entity2 tissues (mean        SD 3.84        0.08) compared with adjacent normal mucosa (mean        SD 1.17        0.75, P   =   0.001). Furthermore, a higher expression of @entity6 mRNA was found in @entity2 tissues (mean        SD 2.73        0.69) when compared with normal tissues (mean        SD 1.06        0.07, P   =   0.001). Our findings indicated that advanced @entity2 ( @entity2 ) stage (P   =   0.024) and histological grade (poorly differentiated, P   =   0.013) and distant @entity1 (P   =   0.001) were correlated with expression of @entity5 . Moreover, high expression of @entity6 showed significant association with early stage @entity3 ( @entity2 ) (P   =   0.038). In conclusion, the expression of @entity5 and @entity6 mRNAs was significantly increased in @entity2 tissues compared with adjacent normal tissues. We found that advanced @entity2 stage and histological grade and distant @entity1 were correlated with expression of @entity5 , while high expression of @entity6 showed significant association with early stage @entity3 ( @entity2 ) stage and overexpression of @entity5 may be associated with progression of @entity3 .

title: Overexpression of interleukins @entity6 and XXXX with poor prognosis in @entity3 induces @entity1 .

answer: @entity5


abstract: UNASSIGNED: Current evidences indicated that a group of soluble mediators called chemokines is involved in @entity2 growth and @entity1 . The association of @entity5 with @entity2 cell migration was previously found, and its expression was related to angiogenesis, @entity2 progression, and @entity1 in many kinds of @entity4 in @entity0 and animal models. Furthermore, it has been showed that @entity6 plays its role as either a proteome of @entity2 progression or antitumor indifferent @entity2 models. To investigate the messenger RNA (mRNA) expressions of @entity5 and @entity6 in @entity0 with @entity3 ( @entity3 ) and non- @entity2 tissue, quantitative real-time PCR was used in the study. Our results showed that expression of @entity5 mRNA was significantly increased in @entity2 tissues (mean        SD 3.84        0.08) compared with adjacent normal mucosa (mean        SD 1.17        0.75, P   =   0.001). Furthermore, a higher expression of @entity6 mRNA was found in @entity2 tissues (mean        SD 2.73        0.69) when compared with normal tissues (mean        SD 1.06        0.07, P   =   0.001). Our findings indicated that advanced @entity2 ( @entity2 ) stage (P   =   0.024) and histological grade (poorly differentiated, P   =   0.013) and distant @entity1 (P   =   0.001) were correlated with expression of @entity5 . Moreover, high expression of @entity6 showed significant association with early stage @entity3 ( @entity2 ) (P   =   0.038). In conclusion, the expression of @entity5 and @entity6 mRNAs was significantly increased in @entity2 tissues compared with adjacent normal tissues. We found that advanced @entity2 stage and histological grade and distant @entity1 were correlated with expression of @entity5 , while high expression of @entity6 showed significant association with early stage @entity3 ( @entity2 ) stage and overexpression of @entity5 may be associated with progression of @entity3 .

title: Overexpression of interleukins XXXX and @entity5 with poor prognosis in @entity3 induces @entity1 .

answer: @entity6


abstract: OBJECTIVE: We sought to examine the surgical trends and utilization of treatment for mixed @entity1 among female Medicare beneficiaries. METHODS: Data was obtained from a 5% national random sample of outpatient and carrier claims from 2000 to 2011. Included were female @entity0 65 and older, diagnosed with mixed @entity1 , who underwent surgical treatment identified by Current Procedural Terminology, Fourth Edition ( @entity2 -4) codes. Urodynamics (UDS) before initial and secondary procedure were also identified using CPT-4 codes. Procedural trends and utilization of UDS were analyzed. RESULTS: Utilization of UDS increased during the study period, from 38.4% to 74.0% prior to initial surgical intervention, and from 28.6% to 62.5% preceding re-intervention. Sling surgery (63.0%) and injectable bulking agents (28.0%) were the most common surgical treatments adopted, followed by sacral nerve stimulation (SNS) (4.8%) and Burch (4.0%) procedures. Re-intervention was performed in 4.0% of @entity0 initially treated with sling procedures and 21.3% of @entity0 treated with bulking agents, the majority of whom (51.7% and 76.3%, respectively) underwent injection of a bulking agent. Risk of re-intervention was not different among those who did or did not receive urodynamic tests prior to the initial procedure (8.5% vs. 9.3%) CONCLUSIONS: Sling and bulk agents are the most common treatment for MUI. Preoperative urodynamic testing was not related to risk of re-intervention following surgery for mixed @entity1 in this cohort. Neurourol. Urodynam.    2015 Wiley Periodicals, Inc.

title: Trends in surgical management and pre-operative urodynamics in female medicare beneficiaries with mixed XXXX .

answer: @entity1


abstract: PURPOSE: Urachal @entity3 is a rare @entity1 . Its histological phenotype is similar to that of primary bladder and @entity2 . The aim of this study was to explore the expression and prognostic relevance of 6 select protein markers of @entity3 , including @entity5 , Ki67, @entity8 , @entity7 , @entity9 and @entity6 , which were formerly shown to be prognostic in @entity4 and @entity2 . MATERIALS AND METHODS: Clinical and followup data were obtained on a total of 26  @entity0 with @entity3 treated at 2 university hospitals. Immunohistochemical analysis of @entity5 , Ki67, @entity8 , @entity7 , @entity9 and @entity6 expression was performed in samples from 15 @entity0 . Clinicopathological parameters and immunohistochemical results were tested for prognostic value on univariable and multivariable analyses. RESULTS: Followup was 50 months. Five-year overall and progression-free survival was 46% and 32%, respectively. On multivariable analysis a positive resection margin was an independent predictor of poor overall survival (p  =  0.025). @entity8 (p = 0.0431), @entity9 (p = 0.0052), Ki67 (p = 0.0006) and @entity5 (p = 0.0024) expression rates were significantly increased in @entity3 cells compared to normal urothelium. @entity9 was elevated in Sheldon @entity1 stage IIIA compared to IIIB or greater (p = 0.0048). None of the analyzed protein markers was associated with survival. CONCLUSIONS: The independent prognostic value of a positive resection margin underlines the importance of complete surgical removal of @entity3 combined with en bloc resection of the median umbilical ligament and umbilicus. Our results in a limited number of samples show that Ki67, @entity5 , @entity8 and @entity9 expression is enhanced but has no prognostic significance in @entity3 .

title: XXXX of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis.

answer: @entity4


abstract: BACKGROUND: Anti- @entity3 monoclonal antibodies (panitumumab [P] and cetuximab [C]) are approved and effective only in @entity4 wild-type @entity0 with advanced @entity2 . The purpose of our meta-analysis is to evaluate the real effects of C and P in @entity4 wild-type @entity0 treated in randomized trials. @entity0 AND METHODS: Eligible studies included prospective, randomized, and controlled trials in which either C or P had been added to standard antineoplastic therapy or best supportive care and data for @entity4 wild-type @entity0 only had been calculated. Six thousand three hundred ninety-five @entity0 ' @entity1 samples have been analyzed (total wild-type n = 3,254; experimental arm n = 1,608; control arm n = 1,646). Relative risks (RRs) with 95% confidence intervals (CIs) for response rate were calculated, as well as hazard ratios (HRs)for progression-free survival (PFS) and overall survival. RESULTS: The overall RR of response rate is 1.69 (p = 0.003) in all trials. The overall HRs for PFS and survival are 0.65 (p = 0.0006) and 0.84 (p = 0.03), respectively, and both are significant. The HRs for PFS and survival in C trials are 0.64 and 0.79, respectively, and 0.65 and 0.87, respectively, in P trials, although only the results achieved in P trials are significant (p = 0.0007 and p = 0.03). Both response rate (RR = 10.94) and PFS (HR = 0.51) have increased more in pretreated @entity0 than in first-line trials. CONCLUSION: The addition of anti- @entity3 monoclonal antibodies to standard anticancer therapy in @entity4 wild-type @entity2 showed an overall significantly increased risk of objective response rate and increased progression-free and overall survival. Only the results achieved in P randomized trials are significant, and the strongest results have been achieved in pretreated @entity0 .

title: Cetuximab and panitumumab in XXXX wild-type @entity2 : a meta-analysis.

answer: @entity4


abstract: BACKGROUND: Anti- @entity3 monoclonal antibodies (panitumumab [P] and cetuximab [C]) are approved and effective only in @entity4 wild-type @entity0 with advanced @entity2 . The purpose of our meta-analysis is to evaluate the real effects of C and P in @entity4 wild-type @entity0 treated in randomized trials. @entity0 AND METHODS: Eligible studies included prospective, randomized, and controlled trials in which either C or P had been added to standard antineoplastic therapy or best supportive care and data for @entity4 wild-type @entity0 only had been calculated. Six thousand three hundred ninety-five @entity0 ' @entity1 samples have been analyzed (total wild-type n = 3,254; experimental arm n = 1,608; control arm n = 1,646). Relative risks (RRs) with 95% confidence intervals (CIs) for response rate were calculated, as well as hazard ratios (HRs)for progression-free survival (PFS) and overall survival. RESULTS: The overall RR of response rate is 1.69 (p = 0.003) in all trials. The overall HRs for PFS and survival are 0.65 (p = 0.0006) and 0.84 (p = 0.03), respectively, and both are significant. The HRs for PFS and survival in C trials are 0.64 and 0.79, respectively, and 0.65 and 0.87, respectively, in P trials, although only the results achieved in P trials are significant (p = 0.0007 and p = 0.03). Both response rate (RR = 10.94) and PFS (HR = 0.51) have increased more in pretreated @entity0 than in first-line trials. CONCLUSION: The addition of anti- @entity3 monoclonal antibodies to standard anticancer therapy in @entity4 wild-type @entity2 showed an overall significantly increased risk of objective response rate and increased progression-free and overall survival. Only the results achieved in P randomized trials are significant, and the strongest results have been achieved in pretreated @entity0 .

title: Cetuximab and panitumumab in @entity4 wild-type XXXX : a meta-analysis.

answer: @entity2


abstract: PURPOSE: Diagnosing and operating pediatric @entity0 with @entity6 posed a greater diagnostic challenge for physicians during the early twentieth century. At the time, an @entity5 was indistinctively diagnosed as a @entity2 , encompassing a broad category of @entity5 pathologies. The treatment and surgical interventions followed for @entity0 diagnosed with @entity2 is not well-described in the literature from this time. METHODS: Following IRB approval, and through the courtesy of the Alan Mason Chesney Archives, we reviewed the Johns Hopkins Hospital surgical files from 1896-1912. @entity0 18 years or younger, who underwent surgical intervention by @entity4 for suspected @entity1 , were selected. RESULTS: Of the eight pediatric cases diagnosed with @entity2 by @entity4 , four cases were later diagnosed as @entity7 by Dr. @entity4 in 1925. Of the remaining four pediatric cases, one was diagnosed as a @entity2 and another as a @entity3 . We describe the remaining two cases. CONCLUSION: These examples illustrate @entity4 's approach to treating @entity5 diagnosed as @entity2 in pediatric @entity0 , focusing on an initial decompression and followed by a thorough surgical exploration for @entity1 . Furthermore, these cases demonstrate @entity4 's early attempts to manage such lesions in @entity0 and highlight the challenges faced in diagnosing and localizing @entity6 within this group of @entity0 .

title: Harvey XXXX 's early experience with @entity2 .

answer: @entity4


abstract: PURPOSE: Diagnosing and operating pediatric @entity0 with @entity6 posed a greater diagnostic challenge for physicians during the early twentieth century. At the time, an @entity5 was indistinctively diagnosed as a @entity2 , encompassing a broad category of @entity5 pathologies. The treatment and surgical interventions followed for @entity0 diagnosed with @entity2 is not well-described in the literature from this time. METHODS: Following IRB approval, and through the courtesy of the Alan Mason Chesney Archives, we reviewed the Johns Hopkins Hospital surgical files from 1896-1912. @entity0 18 years or younger, who underwent surgical intervention by @entity4 for suspected @entity1 , were selected. RESULTS: Of the eight pediatric cases diagnosed with @entity2 by @entity4 , four cases were later diagnosed as @entity7 by Dr. @entity4 in 1925. Of the remaining four pediatric cases, one was diagnosed as a @entity2 and another as a @entity3 . We describe the remaining two cases. CONCLUSION: These examples illustrate @entity4 's approach to treating @entity5 diagnosed as @entity2 in pediatric @entity0 , focusing on an initial decompression and followed by a thorough surgical exploration for @entity1 . Furthermore, these cases demonstrate @entity4 's early attempts to manage such lesions in @entity0 and highlight the challenges faced in diagnosing and localizing @entity6 within this group of @entity0 .

title: Harvey @entity4 's early experience with XXXX .

answer: @entity2


abstract: Central @entity1 (CNP) after @entity4 has not been studied in sufficient detail and published studies have only included @entity0 with cerebral artery infarct or @entity8 . This study evaluates the prevalence and factors associated with CNP after @entity2 ( @entity9 ). This observational study included all @entity0 admitted to our @entity4 unit for @entity9 between January 2002 and December 2007. Clinical data for each @entity0 were collected prospectively and were combined with retrospective review of neuroradiological imaging. @entity9 @entity0 were systematically examined at the outpatient clinic at 6 months, 12 months, and annually thereafter, and information on long-term functional outcome, including the presence of CNP, were obtained by open-ended questions. A standardized CNP assessment was performed during the last outpatient visit and was based on the @entity0 's interview and clinical examination. @entity5 characteristics were assessed by the DN4-questionnaire. CNP was considered when the @entity0 met the following criteria: painful area within the area of sensory abnormalities and follow-up MRI showing brain parenchymal lesion. Among the 43 @entity0 admitted for @entity9 , seven (16%) developed CNP during the first year of follow-up. Standardized CNP assessment was performed 24.9    11.6 months after @entity9 : eight @entity0 (19%) suffered from CNP. @entity3 (87 vs. 17%, p < 0.001), @entity3 (62 vs. 20%, p = 0.03), @entity6 (75 vs. 23%, p = 0.009), right-sided lesion on initial MRI (62 vs. 17%, p = 0.017), thalamic (37 vs. 0%, p = 0.005) and basal ganglia involvement (25 vs. 0%, p = 0.03) and vein of @entity7 (25 vs. 0%) were significantly associated with CNP. Despite several methodological limitations, CNP after @entity9 seems to be frequent, accounting for one-fifth of all cases of @entity9 . Some clinical and radiological factors might contribute to the development of CNP.

title: Central XXXX after cerebral venous thrombosis is not so uncommon: an observational study.

answer: @entity1


abstract: @entity5 ( @entity5 ) is caused by a germline mutations in DNA mismatch repair genes and is a @entity3 , responsible for 2-5% of all @entity2 ( @entity2 ) cases. Mutation carriers have a 60-85% risk of developing @entity2 . With the increasing use of genetic predisposition testing, @entity0 and health care providers must decide on @entity1 risk-reduction strategies. The @entity1 observed in families with @entity5 are diagnosed at an unusually early age and may be multiple. The decision about which surgery is suitable should be made on the basis of @entity0 factors and preferences, with special emphasis on age, comorbidity, sphincteric function, and the ability of the @entity0 to cope with intensive surveillance. Colectomy decreases the risk of second @entity2 significantly. The estimated lifetime risk for @entity4 is 40-60% in @entity0 with @entity5 , and the mean age at diagnosis is around 50 years. This risk equals or exceeds the risk of @entity2 . The optimal management of the elevated risk for @entity1 in carriers of mutations for @entity2 is unclear. @entity0 who are gene mutation carriers should receive counseling about colectomy, and if @entity0 , prophylactic hysterectomy and bilateral oophorectomy.

title: Prophylactic surgery in XXXX .

answer: @entity5


abstract: The objective was to investigate corneal re-epithelialisation of surface-modified polymethacrylate hydrogel implants in order to evaluate them as potential materials for an artificial @entity0 . @entity6 hydrogels were modified with @entity2 and then coated with different extracellular matrix proteins (collagen I, IV, laminin and fibronectin). The modified hydrogels were surgically implanted into @entity1 corneas maintained in a 3-D culture system for 5 days. The epithelial growth across the implant surface was evaluated using fluorescent, light and electron microscopy. Full epithelialisation was achieved on @entity3 -modified hydrogels after coating with collagen IV. Hydrogels modified with @entity3 but without further coating only showed partial re-epithelialisation. Hydrogels modified with other @entity2 ( @entity5 or @entity4 ) showed only partial re-epithelialisation; further coating with extracellular matrix proteins improved epithelialisation of these surfaces but did not result in complete re-epithelialisation. Evaluation of the corneas implanted with the @entity3 -modified hydrogels coated with collagen IV showed that the artificial corneas remain clear, integrate well and become covered by a healthy stratified epithelium. In conclusion the @entity3 surface-modified hydrogel coated with collagen IV supported the growth of a stable stratified epithelium. With further refinement this hydrogel has the potential to be used clinically for an artificial @entity0 .

title: Corneal epithelialisation on surface-modified hydrogel implants: artificial XXXX .

answer: @entity0


abstract: Exciton model for description of experimentally determined excitation energy transfer from carotenoids to @entity0 in the LHC-II trimer of @entity1 is presented. Such an approach allows connecting the excitonic states to the spatial structure of the complex and hence descriptions of advancements of the initially created excitations in space and time. Carotenoids were excited at 490  nm and at 500  nm and induced absorbance changes probed in the Chl Q(y) region to provide kinetic data that were interpreted by using the results from exciton calculations. Calculations included the 42 @entity0 and the 12 carotenoids of the complex, Soret, Q(x) and Q(y) states of the @entity0 , and the main absorbing S(2) state of the carotenoids. According to the calculations excitation at 500  nm populates mostly a mixed Lut S(2) Chl a Soret state, from where excitation is transferred to the Q(x) and Q(y) states of the Chl a's on the stromal side. Internal conversion of the mixed state to a mixed Lut S(1) and Chl a Q(y) state provides a channel for Lut S(1) to Chl a Q(y) energy transfer. The results from the calculations support a picture where excitation at 490  nm populates primarily a mixed @entity2 S(2) Chl b Soret state. From this state excitation from @entity2 is transferred to iso-energetic Chl b Soret states or via internal conversion to S(1) Chl b Q(y) states. From the Soret states excitation proceeds via internal conversion to Q(y) states of Chl b's mostly on the lumenal side. A rapid Chl b to Chl a transfer and subsequent transfer to the stromal side Chl a's and to the final state completes the process after 490  nm excitation. The interpretation is further supported by the fact that excitation energy transfer kinetics after excitation of @entity2 at 490  nm and the Chl b Q(y) band at 647  nm (Linnanto et al., Photosynth Res 87:267-279, 2006) are very similar.

title: Excitation energy transfer in the LHC-II trimer: from carotenoids to XXXX in space and time.

answer: @entity0


abstract: The mitochondrial respiratory chain is a major source of reactive @entity0 species (ROS) under pathological conditions including @entity4 and reperfusion. Limitation of electron transport by the inhibitor @entity8 immediately before @entity2 decreases the production of ROS in cardiac myocytes and reduces damage to mitochondria. We asked if ROS generation by intact mitochondria during the oxidation of complex I substrates ( @entity6 , @entity7 / @entity9 ) occurred from complex I or III. ROS production by mitochondria of @entity1 hearts and corresponding submitochondrial particles was studied. ROS were measured as @entity3 using the amplex red assay. In mitochondria oxidizing complex I substrates, @entity8 inhibition did not increase @entity3 . Oxidation of complex I or II substrates in the presence of @entity10 markedly increased @entity3 . @entity8 prevented @entity10 -induced @entity3 production in mitochondria with complex I substrates but not with complex II substrates. @entity11 scavenged @entity3 . In contrast to intact mitochondria, blockade of complex I with @entity8 markedly increased @entity3 production from submitochondrial particles oxidizing the complex I substrate @entity5 . ROS are produced from complex I by the @entity5 dehydrogenase located in the matrix side of the inner membrane and are dissipated in mitochondria by matrix antioxidant defense. However, in submitochondrial particles devoid of antioxidant defense ROS from complex I are available for detection. In mitochondria, complex III is the principal site for ROS generation during the oxidation of complex I substrates, and @entity8 protects by limiting electron flow into complex III.

title: Production of reactive XXXX species by mitochondria: central role of complex III.

answer: @entity0


abstract: PURPOSE: Few studies have assessed physical and psychological status in long-term survivors of childhood solid @entity1 in Japan. For @entity0 with such diseases diagnosed and treated in our hospital, our purpose was to clarify the physical and psychological status of long-term survivors and their parents. METHODS: Subjects were 56 @entity0 who were diagnosed at our institution as having a childhood malignant solid @entity1 between 1982 and 2005 and had been alive for at least 5 years after treatment. Surveys were sent and returned by mail. RESULTS: Of the 56 @entity0 surveyed, 32 responded. The current health condition and psychosocial status of survivors were evaluated as good by their parents. However, psychological tests revealed @entity2 in 28.1% of the @entity0 . Severe posttraumatic stress associated with the @entity0 's disease and its treatment was present in 15.6% of the parents. CONCLUSION: Physical status of long-term survivors of childhood malignant solid @entity1 was good in general. However, psychological tests revealed @entity2 in some of the @entity0 and posttraumatic stress in the parents. Considering the diversity of both the diseases and their clinical course, a qualitative study is warranted for further analysis.

title: Physical and psychological outcome in long-term survivors of childhood malignant solid XXXX in Japan.

answer: @entity1


abstract: Prior to the era of disease-modifying therapies ( @entity5 ), @entity2 ( @entity2 ) was linked to reduced rates of @entity1 . Early use of immunosuppressors (IS) in @entity2 justifies the follow-up of @entity0 to evaluate a possible increase in the incidence of @entity1 in these @entity0 . We performed a descriptive study of @entity2 @entity0 with a documented oncological event. Among the 22,563 @entity2 @entity0 in the EDMUS databases, @entity0 with a history of @entity1 were identified, and @entity1 risk in a @entity2 cohort (CARIMS) was evaluated. Four groups were defined: (A) @entity2 @entity0 without @entity1 receiving @entity5 or not, (B) @entity2 @entity0 with @entity1 but without any history of @entity5 , (C) @entity2 @entity0 with @entity1 who received an immunomodulator (IM), and/or (D) @entity2 @entity0 treated with an IS. A total of 9,269 @entity0 (44.1%) had a history of @entity5 (52% IM; 18% IS; 30% both); 253 @entity0 with @entity2 and @entity1 were identified, 182 had a history of @entity5 . The mean duration of @entity5 was longer for group D (A: 3.6 years vs. D: 4.9 years; P < 0.01). There was no increased risk of @entity1 among @entity0 treated exclusively with IM. IS treatment (P = 0.043) and the duration of exposure (P < 0.001) significantly increased the risk of @entity1 , especially @entity4 , as observed in other @entity3 . This result could influence the attitude of the medical profession with respect to the benefit to risk ratio when proposing @entity5 to @entity2 @entity0 .

title: @entity1 and XXXX in the era of disease-modifying treatments.

answer: @entity2


abstract: Prior to the era of disease-modifying therapies ( @entity5 ), @entity2 ( @entity2 ) was linked to reduced rates of @entity1 . Early use of immunosuppressors (IS) in @entity2 justifies the follow-up of @entity0 to evaluate a possible increase in the incidence of @entity1 in these @entity0 . We performed a descriptive study of @entity2 @entity0 with a documented oncological event. Among the 22,563 @entity2 @entity0 in the EDMUS databases, @entity0 with a history of @entity1 were identified, and @entity1 risk in a @entity2 cohort (CARIMS) was evaluated. Four groups were defined: (A) @entity2 @entity0 without @entity1 receiving @entity5 or not, (B) @entity2 @entity0 with @entity1 but without any history of @entity5 , (C) @entity2 @entity0 with @entity1 who received an immunomodulator (IM), and/or (D) @entity2 @entity0 treated with an IS. A total of 9,269 @entity0 (44.1%) had a history of @entity5 (52% IM; 18% IS; 30% both); 253 @entity0 with @entity2 and @entity1 were identified, 182 had a history of @entity5 . The mean duration of @entity5 was longer for group D (A: 3.6 years vs. D: 4.9 years; P < 0.01). There was no increased risk of @entity1 among @entity0 treated exclusively with IM. IS treatment (P = 0.043) and the duration of exposure (P < 0.001) significantly increased the risk of @entity1 , especially @entity4 , as observed in other @entity3 . This result could influence the attitude of the medical profession with respect to the benefit to risk ratio when proposing @entity5 to @entity2 @entity0 .

title: XXXX and @entity2 in the era of disease-modifying treatments.

answer: @entity1


abstract: BACKGROUND: Although stent placement is increasingly performed, colostomy still is considered the gold standard for emergent relief of malignant @entity1 (MCO). This study aimed to compare hospital costs and clinical outcomes between @entity0 undergoing colostomy and those undergoing stenting for the management of MCO. METHODS: A retrospective claims analysis of the Medicare Provider Analysis and Review (MedPAR) data set was conducted to identify inpatient hospitalizations for colostomy or stent placement for the treatment of @entity1 (2007-2008). The outcomes evaluated using MedPAR compared the total length of hospital stay (LOS) and the costs associated with both techniques. Because MedPAR is a claims data set that does not provide outcomes at a @entity0 level, a single-institution retrospective case-control study was conducted in which each stent placement @entity0 was matched with two colostomy @entity0 during the same period. Outcome measures (institutional data) were used to compare rates of treatment success, postprocedure LOS, and reinterventions between the two cohorts. RESULTS: The MedPAR data evaluated 778 stent placements and 5,868 colostomy hospitalizations. There were no differences in gender, age distribution, or comorbidity between the two groups. Compared with colostomy, the median LOS (8 vs. 12 days; p<0.0001) and the median cost ( 15,071 vs.  24,695; p<0.001) per claim were significantly less for stent placement. Stent placement was more commonly performed at urban versus rural hospitals (84% vs. 16%; p<0.0001), teaching versus nonteaching hospitals (56% vs. 44%; p=0.0058) and larger versus smaller institutions (mean bed capacity, 331 vs. 227; p<0.0001). The institution data included 12 @entity0 who underwent stent placement and 24 who underwent colostomy. Although both methods were technically successful, the median postprocedure LOS (2.17 vs. 10.58 days; p=0.0004) and the rate of readmissions for complications (0% vs. 25%; p=0.01) were significantly lower for stent placement. CONCLUSION: Although the technical and clinical outcomes for colostomy and stent placement appear comparable, stent placement is less costly and associated with shorter LOS and fewer complications. Dissemination of stent placement beyond large teaching hospitals located in urban areas as a treatment for MCO is important given its implications for @entity0 care and resource use.

title: Endoscopic stenting versus surgical colostomy for the management of malignant XXXX : comparison of hospital costs and clinical outcomes.

answer: @entity1


abstract: The effects of the @entity0 -promoting @entity4 @entity2 ( @entity3 ) on the morphology and growth properties of @entity1 cells were examined. The morphology of these cells was changed within 30 min following treatment with 0.1 microgram of @entity3 per ml; they became smaller and refractile with long beady processes. Such changes were observed in both logarithmic and confluent cultures and lasted about 72 hr. Subsequent treatments were much less effective in inducing these changes. Scanning electron microscopy showed cell retraction and rounding as the most significant immediate effects of @entity3 treatment; many cells remained partially rounded 48 hr afterwards. Long-term surface modifications ascribable to @entity3 treatment were not detected. @entity3 had only minor effects on the growth of cultured C3H/10T1/2 cells in the presence of 10% fetal calf serum. Slight increases in plating efficiencies and saturation densities were generally observed in the presence of @entity3 but not with the related non- @entity0 -promoting compound @entity5 . The cells grew slowly in 1% fetal calf serum and demonstrated serum batch-dependent alterations in their growth properties when exposed to @entity3 . Under conditions that produce doubling times of 70 hr or greater, @entity3 , but not @entity5 , reduced the doubling time to about 50 hr. Saturation densities were also increased by @entity3 in 1% fetal calf serum. The effects of @entity3 on the growth of an oncogenically transformed variant of C3H/10T1/2 were quite different. While minimal effects of @entity3 were observed quite different. While minimal effects of @entity3 were observed when transformed cells were treated in the presence of 10% total calf serum, @entity3 treatment in 1% fetal calf serum significantly inhibited cell growth.

title: Effect of XXXX on the morphology and growth of C3H/10T1/2 @entity1 embryo cells.

answer: @entity2


abstract: The effects of the @entity0 -promoting @entity4 @entity2 ( @entity3 ) on the morphology and growth properties of @entity1 cells were examined. The morphology of these cells was changed within 30 min following treatment with 0.1 microgram of @entity3 per ml; they became smaller and refractile with long beady processes. Such changes were observed in both logarithmic and confluent cultures and lasted about 72 hr. Subsequent treatments were much less effective in inducing these changes. Scanning electron microscopy showed cell retraction and rounding as the most significant immediate effects of @entity3 treatment; many cells remained partially rounded 48 hr afterwards. Long-term surface modifications ascribable to @entity3 treatment were not detected. @entity3 had only minor effects on the growth of cultured C3H/10T1/2 cells in the presence of 10% fetal calf serum. Slight increases in plating efficiencies and saturation densities were generally observed in the presence of @entity3 but not with the related non- @entity0 -promoting compound @entity5 . The cells grew slowly in 1% fetal calf serum and demonstrated serum batch-dependent alterations in their growth properties when exposed to @entity3 . Under conditions that produce doubling times of 70 hr or greater, @entity3 , but not @entity5 , reduced the doubling time to about 50 hr. Saturation densities were also increased by @entity3 in 1% fetal calf serum. The effects of @entity3 on the growth of an oncogenically transformed variant of C3H/10T1/2 were quite different. While minimal effects of @entity3 were observed quite different. While minimal effects of @entity3 were observed when transformed cells were treated in the presence of 10% total calf serum, @entity3 treatment in 1% fetal calf serum significantly inhibited cell growth.

title: Effect of @entity2 on the morphology and growth of C3H/10T1/2 XXXX embryo cells.

answer: @entity1


abstract: For many years there was doubt if gamma-irradiated @entity3 materials could be sterilized with @entity4 . It was feared that toxic concentrations of @entity5 ( @entity5 ) might originate with this procedure. We investigated the various possibilities of @entity5 formation. Gamma-irradiated @entity3 tubes were resterilized with @entity4 and the @entity5 concentrations determined by gas chromatography. The @entity5 concentrations at the end of sterilization ranged from 240 to 436 ppm depending upon the composition of the tubes. After 4 d they ranged from < 5 to 280 ppm and after 21 d from < 5 to 218 ppm. For comparison were examined @entity3 tubes which were not gamma-irradiated but @entity4 sterilized only. We extracted < 5 to 23 ppm @entity5 from them. @entity3 tubes gas sterilized only and retaining 44 to 9300 ppm @entity4 were submerged in physiological @entity2 solution for 2 h. The @entity5 concentrations formed by this procedure ranged from 43 to 75 ppm. After 4 d aeration before begin of extraction they decreased to < 5, 10 and 16 ppm. @entity3 tubes aerated for 5 or 7 d, containing at least 236 ppm @entity5 did not demonstrate any effect upon cultures of @entity0 fibroblasts. The toxic concentrations of @entity5 in our own animal- and cell culture experiments were 12 000 ppm or higher. Other investigators found no damaging effect on @entity1 fibroblasts by adding 20 000 ppm @entity5 . It appears to be sufficiently proven that gamma-irradiated @entity3 items may be resterilized with @entity4 and used in @entity0 provided they they have been adequately aerated.

title: [Gamma-rays and XXXX sterilization (author's transl)].

answer: @entity4


abstract: The extensive bilateral craniectomy with opening of the dura offers the possibility of rapid reduction of intracranial pressure. The reactive @entity4 with imminent or beginning decompensation indicates the need for operation. Technically, it is easy to carry out bilateral cranial decompression. The open dura results in no additional postoperative problem. 21 of our 30 @entity0 died postoperatively within 8.6 days, 2 @entity0 in state of @entity2 after 4 and 16 months. 2 @entity0 are living now with @entity2 for 17 and 20 months. All apallic @entity0 show a massive @entity3 internus. 5 @entity0 demonstrate a full restitution. In this group there is an interval of 3.2 days between accident and operation, the duration of the postoperative unconsciousness was 9.4 days. In @entity0 a spontaneous ossification of the @entity1 may be expected if the periost is conserved. The article compares the bilateral craniectomy with other conservative and operative methods of treatment.

title: [Bilateral craniectomy in the treatment of severe traumatic XXXX ].

answer: @entity4


abstract: To explore the importance of equol on health outcomes in future studies, it was necessary to develop a method to reduce equol production. Female monkeys (n = 22) fed a soy diet were treated twice daily with vehicle (control; n = 4), @entity2 (2.5 mg/kg; n = 4), @entity0 (125 mg/d; n = 3), @entity4 (1000 mg/d; n = 4), @entity1 (100 mg/d; n = 3) or @entity4 + @entity1 (n = 4). Plasma samples were collected 4 h postfeeding at baseline, after 4 wk of treatment and 8 wk after the end of treatment and analyzed for @entity6 concentrations. Fecal swabs were collected at baseline and at the end of antibiotic treatment for analysis of Gram(+) and Gram(-) bacterial growth. Equol concentrations were reduced (P < 0.05) compared with baseline by 80, 93, 98 and 99% after treatment with @entity0 (955 +/- 164 vs. 193 +/- 53 nmol/L), @entity4 (545 +/- 211 vs. 37.1 +/- 17.6 nmol/L), @entity1 (607 +/- 163 vs. 8.9 +/- 8.2 nmol/L) and @entity4 + @entity1 (721 +/- 169 vs. 17.4 +/- 17.3 nmol/L), respectively. @entity5 concentrations were increased (P < 0.05) compared with baseline by treatment with @entity2 (336 +/- 87 vs. 576 +/- 76 nmol/L), @entity4 (168 +/- 67 vs. 374 +/- 15 nmol/L), and @entity4 + @entity1 (166 +/- 35 vs. 384 +/- 78 nmol/L). Similar increases (P < 0.05) in @entity7 were observed after treatment with @entity4 (31.2 +/- 6.2 vs. 479 +/- 188 nmol/L) and @entity0 (56.0 +/- 27.9 vs. 414 +/- 212 nmol/L). @entity6 concentrations returned to baseline values after antibiotic treatment was terminated. Gram(+) bacterial growth was reduced by all treatments, including Control, compared with baseline. In conclusion, treatment with antibiotics resulted in a marked reduction in plasma equol concentrations and altered plasma @entity6 patterns in @entity3 .

title: Treatment with antibiotics reduces plasma equol concentration in XXXX ( @entity3 ).

answer: @entity3


abstract: To explore the importance of equol on health outcomes in future studies, it was necessary to develop a method to reduce equol production. Female monkeys (n = 22) fed a soy diet were treated twice daily with vehicle (control; n = 4), @entity2 (2.5 mg/kg; n = 4), @entity0 (125 mg/d; n = 3), @entity4 (1000 mg/d; n = 4), @entity1 (100 mg/d; n = 3) or @entity4 + @entity1 (n = 4). Plasma samples were collected 4 h postfeeding at baseline, after 4 wk of treatment and 8 wk after the end of treatment and analyzed for @entity6 concentrations. Fecal swabs were collected at baseline and at the end of antibiotic treatment for analysis of Gram(+) and Gram(-) bacterial growth. Equol concentrations were reduced (P < 0.05) compared with baseline by 80, 93, 98 and 99% after treatment with @entity0 (955 +/- 164 vs. 193 +/- 53 nmol/L), @entity4 (545 +/- 211 vs. 37.1 +/- 17.6 nmol/L), @entity1 (607 +/- 163 vs. 8.9 +/- 8.2 nmol/L) and @entity4 + @entity1 (721 +/- 169 vs. 17.4 +/- 17.3 nmol/L), respectively. @entity5 concentrations were increased (P < 0.05) compared with baseline by treatment with @entity2 (336 +/- 87 vs. 576 +/- 76 nmol/L), @entity4 (168 +/- 67 vs. 374 +/- 15 nmol/L), and @entity4 + @entity1 (166 +/- 35 vs. 384 +/- 78 nmol/L). Similar increases (P < 0.05) in @entity7 were observed after treatment with @entity4 (31.2 +/- 6.2 vs. 479 +/- 188 nmol/L) and @entity0 (56.0 +/- 27.9 vs. 414 +/- 212 nmol/L). @entity6 concentrations returned to baseline values after antibiotic treatment was terminated. Gram(+) bacterial growth was reduced by all treatments, including Control, compared with baseline. In conclusion, treatment with antibiotics resulted in a marked reduction in plasma equol concentrations and altered plasma @entity6 patterns in @entity3 .

title: Treatment with antibiotics reduces plasma equol concentration in @entity3 ( XXXX ).

answer: @entity3


abstract: The detailed characteristics of the carotid sinus reflex control of regional pressure-flow relations were compared in @entity0 anesthetized with @entity3 , @entity2 , or @entity1 . The carotid sinuses were isolated and perfused under conditions of controlled pulsatile pressure. Pressure and flow were measured in the ascending aorta and the celiac, mesenteric, renal, and iliac artery. Mean arterial pressure and peripheral resistance were highest under @entity3 and lowest under @entity1 . For cardiac output this relation was reversed. Set point values of reflex gain and overall range of control were similar under @entity3 and @entity1 and lowest under @entity2 . These results were found both before and after bilateral cervical vagotomy. Operating point values of regional resistance were generally largest with @entity3 and smallest with @entity1 . Operating point sensitivities of regional resistances were generally smallest under @entity2 and similar under @entity3 and @entity1 . Vagotomy was associated with increases in set point values of mean arterial pressure, set point gain, and overall range of control under all three anesthetics. With @entity3 as a reference, @entity1 does not depress cardiovascular reflex mechanisms. Carotid sinus reflexes under @entity1 were as sensitive and well maintained as they were under @entity3 . These reflexes were significantly depressed under @entity2 compared with @entity3 .

title: Effects of anesthesia on carotid sinus reflex control of arterial hemodynamics in the XXXX .

answer: @entity0


abstract: @entity5 and increased circumferential LV strain have been demonstrated in @entity0 with severe @entity3 ( @entity3 ) and normal @entity5 ( @entity5 ). Biplane myocardial mechanics normalize after aortic valve replacement (AVR). This study objective was to examine LV mechanics before and soon after AVR in @entity0 with @entity3 and LV @entity2 . Paired echocardiographic studies before and soon (7    3 days) after AVR were analyzed in 64 @entity0 with severe @entity3 : 32 with normal @entity5 (>=  50%), 16 with mild to moderate @entity5 ( @entity5 <36% to 50%), and 16 with severe @entity5 ( @entity5  <= 35%). @entity1 was assessed from 3 apical views (average of 18 segments) and circumferential function was assessed at mid-LV and apical levels (average of 6 segments per view). Strain, strain rate, and mid-LV and apical rotations were measured using 2-dimensional velocity vector imaging. Before AVR (1) longitudinal strain was low in all @entity0 and correlated with @entity5 (   = 0.74, p <0.001), (2) mid-LV circumferential strain was supranormal in @entity0 with normal @entity5 and low in @entity0 with low @entity5 (   = 0.88, p <0.001), and (3) @entity4 was highest in @entity0 with mild to moderate @entity5 . After AVR, @entity5 increased in @entity0 with @entity5 and myocardial mechanics partly normalized. In conclusion, compensatory mechanisms (high circumferential strain in @entity0 with preserved @entity5 and increased @entity4 in @entity0 with mild to moderate @entity5 ) were observed in @entity0 with severe @entity3 . Compensatory mechanics were lost in @entity0 with severe @entity5 . AVR partly reversed these changes in @entity0 with @entity5 .

title: Relation of myocardial mechanics in severe XXXX to left ventricular ejection fraction and response to aortic valve replacement.

answer: @entity3


abstract: In 2008, the worldwide estimated age-standardised incidence rates for @entity2 incidence were 4.7 and 1.5 per 100,000 @entity0 and @entity0 , respectively. @entity2 's overall contribution to the worldwide @entity1 burden is relatively small, but incidence rates have increased over the last three decades throughout the world. This trend has been hypothesised to reflect a combination of technological advances enabling increased detection, but also changes in environmental factors, including population exposure to ionising radiation from fallout, diagnostic tests and treatment for benign and malignant conditions. Studies of the atomic bomb survivors and populations treated with radiotherapy have established radiation as a risk factor for @entity2 , particularly from early life exposure. About 0.62 @entity3 (20%) of the global annual per caput effective radiation dose comes from diagnostic medical and dental radiation for the period of 1997-2007, increased from 0.4 @entity3 for the years 1991-1996. This international trend of increasing population exposure to medical diagnostic sources of radiation, attributed in large part to the growing use of computed tomography scans, but also interventional radiology procedures, has raised concerns about exposure to radiosensitive organs such as the thyroid. Worldwide, medical and dental X-rays constitute the most common type of diagnostic medical exposures, but their contribution to the cumulative effective dose is relatively low, whereas computed tomography scans account for 7.9% of diagnostic radiology examinations but 47% of the collective effective dose from diagnostic radiation procedures in parts of the world. Although the radiation exposure from computed tomography scans is substantially lower than that from radiotherapy, multiple computed tomography scans could result in non-trivial cumulative doses to the thyroid. Studies are currently underway to assess the incidence of @entity1 in large cohorts of @entity0 who received computed tomography scans. National and international efforts have been developed to raise awareness and to standardise procedures for use of computed tomography and interventional radiology procedures in paediatric and general populations.

title: Medical exposure to radiation and XXXX .

answer: @entity2


abstract: OBJECTIVE: We recently demonstrated a correlation between the responses in two target areas, bone and lipids, during treatment with hormone replacement therapy. Whether the same association exists during treatment with selective @entity3 receptor modulators (SERMs) has not been examined before. STUDY DESIGN: This was an exploratory, post hoc analysis of data from two randomized, double-blind, placebo-controlled trials. STUDY POPULATION: From both studies we examined only the Danish subpopulation. Study 1 included 133 @entity0 treated with placebo or @entity5 in four different doses for 12 months, and study 2 included 248 @entity0 treated with @entity4 in three different doses or placebo for 24 months. MEASUREMENTS: @entity1 ( @entity1 ) of the spine and hip was measured semiannually. Serum lipids and biochemical bone markers were determined at each visit. To eliminate interindividual differences, all values were calculated as individual percentage change from baseline. RESULTS: We found a significant correlation between the increase in @entity1 of the spine and hip and the decrease in total @entity2 and low-density lipoprotein. CONCLUSION: Our study showed that, in healthy postmenopausal @entity0 , the @entity0 with the greatest response in @entity1 were also those with the most favorable response in lipid profile during treatment with SERMs.

title: Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective XXXX receptor modulators: @entity5 and @entity4 .

answer: @entity3


abstract: OBJECTIVE: We recently demonstrated a correlation between the responses in two target areas, bone and lipids, during treatment with hormone replacement therapy. Whether the same association exists during treatment with selective @entity3 receptor modulators (SERMs) has not been examined before. STUDY DESIGN: This was an exploratory, post hoc analysis of data from two randomized, double-blind, placebo-controlled trials. STUDY POPULATION: From both studies we examined only the Danish subpopulation. Study 1 included 133 @entity0 treated with placebo or @entity5 in four different doses for 12 months, and study 2 included 248 @entity0 treated with @entity4 in three different doses or placebo for 24 months. MEASUREMENTS: @entity1 ( @entity1 ) of the spine and hip was measured semiannually. Serum lipids and biochemical bone markers were determined at each visit. To eliminate interindividual differences, all values were calculated as individual percentage change from baseline. RESULTS: We found a significant correlation between the increase in @entity1 of the spine and hip and the decrease in total @entity2 and low-density lipoprotein. CONCLUSION: Our study showed that, in healthy postmenopausal @entity0 , the @entity0 with the greatest response in @entity1 were also those with the most favorable response in lipid profile during treatment with SERMs.

title: Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective @entity3 receptor modulators: @entity5 and XXXX .

answer: @entity4


abstract: OBJECTIVE: We recently demonstrated a correlation between the responses in two target areas, bone and lipids, during treatment with hormone replacement therapy. Whether the same association exists during treatment with selective @entity3 receptor modulators (SERMs) has not been examined before. STUDY DESIGN: This was an exploratory, post hoc analysis of data from two randomized, double-blind, placebo-controlled trials. STUDY POPULATION: From both studies we examined only the Danish subpopulation. Study 1 included 133 @entity0 treated with placebo or @entity5 in four different doses for 12 months, and study 2 included 248 @entity0 treated with @entity4 in three different doses or placebo for 24 months. MEASUREMENTS: @entity1 ( @entity1 ) of the spine and hip was measured semiannually. Serum lipids and biochemical bone markers were determined at each visit. To eliminate interindividual differences, all values were calculated as individual percentage change from baseline. RESULTS: We found a significant correlation between the increase in @entity1 of the spine and hip and the decrease in total @entity2 and low-density lipoprotein. CONCLUSION: Our study showed that, in healthy postmenopausal @entity0 , the @entity0 with the greatest response in @entity1 were also those with the most favorable response in lipid profile during treatment with SERMs.

title: Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective @entity3 receptor modulators: XXXX and @entity4 .

answer: @entity5


abstract: PURPOSE: This paper reports a prospective review of @entity0 who, between 2004 and 2007, underwent secondary patellar resurfacing (SPR) due to anterior knee @entity1 after a primary @entity2 ( @entity2 ). The aim was to evaluate the clinical outcomes obtained with the SPR and to compare them with radiological findings. METHODS: A total of twenty-seven consecutive @entity0 met the inclusion criteria. There were twenty-three (85%) @entity0 and four (15%) @entity0 with a median age of 70 years. The @entity0 were evaluated before and after the surgery with the same functional scores and radiological parameters. Bone scintigraphy was also used in the assessment, and a CT-scan was performed in order to evaluate the femoral @entity4 . The median time between @entity2 and SPR was 18 months. RESULTS: With a median follow-up of 23 months, seventeen @entity0 (63%) reported a clear subjective improvement after SPR, and patellofemoral scores (primary outcome measure), KSS and WOMAC (secondary outcome measures) showed a statistically significant improvement following the procedure. There were no significant changes after SPR in the Insall-Salvati ratio, the lateral patellar displacement or the lateral patellar tilt. The mean time between @entity2 and SPR had no statistically significant effect on outcome. The bone scintigraphy revealed increased patellar uptake in seven cases, but this was not related to subsequent improvement after SPR. Rotational computed tomography showed a median internal rotation of the femoral component of 1  . The complications observed were a patellar component loosening and an @entity3 . CONCLUSION: No clinical or radiological parameter was found to be related to the final outcome after SPR. There was a discrepancy between functional scale scores and the @entity0 's subjective satisfaction.

title: Secondary patellar resurfacing in the treatment of @entity1 after XXXX .

answer: @entity2


abstract: PURPOSE: This paper reports a prospective review of @entity0 who, between 2004 and 2007, underwent secondary patellar resurfacing (SPR) due to anterior knee @entity1 after a primary @entity2 ( @entity2 ). The aim was to evaluate the clinical outcomes obtained with the SPR and to compare them with radiological findings. METHODS: A total of twenty-seven consecutive @entity0 met the inclusion criteria. There were twenty-three (85%) @entity0 and four (15%) @entity0 with a median age of 70 years. The @entity0 were evaluated before and after the surgery with the same functional scores and radiological parameters. Bone scintigraphy was also used in the assessment, and a CT-scan was performed in order to evaluate the femoral @entity4 . The median time between @entity2 and SPR was 18 months. RESULTS: With a median follow-up of 23 months, seventeen @entity0 (63%) reported a clear subjective improvement after SPR, and patellofemoral scores (primary outcome measure), KSS and WOMAC (secondary outcome measures) showed a statistically significant improvement following the procedure. There were no significant changes after SPR in the Insall-Salvati ratio, the lateral patellar displacement or the lateral patellar tilt. The mean time between @entity2 and SPR had no statistically significant effect on outcome. The bone scintigraphy revealed increased patellar uptake in seven cases, but this was not related to subsequent improvement after SPR. Rotational computed tomography showed a median internal rotation of the femoral component of 1  . The complications observed were a patellar component loosening and an @entity3 . CONCLUSION: No clinical or radiological parameter was found to be related to the final outcome after SPR. There was a discrepancy between functional scale scores and the @entity0 's subjective satisfaction.

title: Secondary patellar resurfacing in the treatment of XXXX after @entity2 .

answer: @entity1